<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934089</url>
  </required_header>
  <id_info>
    <org_study_id>A0191002</org_study_id>
    <nct_id>NCT00934089</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329</brief_title>
  <official_title>A Phase 2, Single-Masked, Randomized, Crossover Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 Alone and In Combination With Latanoprost</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the effect of PF-04217329, alone and in combination with
      latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood
      samples will be collected to measure the amount of active metabolite of PF-04217329 in the
      plasma following dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) change from baseline</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of the active metabolite of PF-04217329</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic ocular perfusion pressure and mean change from baseline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia scores and change from baseline</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining scores and mean change from baseline</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corneal thickness change from baseline</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corneal endothelial cell counts from baseline</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>PF-04217329 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active study drug + latanoprost vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04217329 + latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active study drug + latanoprost</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04217329</intervention_name>
    <description>Topical ocular solution, once-daily for 14 days</description>
    <arm_group_label>PF-04217329 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost vehicle</intervention_name>
    <description>Topical ocular solution, once-daily for 14 days</description>
    <arm_group_label>PF-04217329 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04217329</intervention_name>
    <description>Topical ocular solution, once-daily for 14 days</description>
    <arm_group_label>PF-04217329 + latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost</intervention_name>
    <description>Topical ocular solution, once-daily for 14 days</description>
    <arm_group_label>PF-04217329 + latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes

          -  Intraocular Pressure (IOP) of at least 22 mmHg and not more than 30 mmHg in either eye
             at 8 AM after discontinuing previous glaucoma treatment

          -  Visual acuity correctable to 20/100 or better in each eye.

        Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye.

          -  Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic
             retinopathy, macular degeneration) in either eye.

          -  Advanced glaucoma or a history of severe central visual field loss in either eye.

          -  History of ocular surgery or trauma in either eye within 6 months of the screening
             visit.

          -  History of ocular infection, ocular inflammation, or laser surgery in either eye
             within 3 months of the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gardena</city>
        <state>California</state>
        <zip>90247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0191002&amp;StudyName=A%20Phase%202%20Study%20Of%20The%2024-Hour%20Intraocular%20Pressure%20Lowering%20And%20Systemic%20Exposure%20Of%20PF-04217329</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <disposition_first_submitted>November 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2010</disposition_first_posted>
  <last_update_submitted>June 28, 2011</last_update_submitted>
  <last_update_submitted_qc>June 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

